Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE: To elucidate the mechanism by which trastuzumab, a humanized monoclonal antibody against HER2 with proven survival benefit in women with HER2-positive metastatic breast cancer, mediates its antitumor activity. EXPERIMENTAL DESIGN: A pilot study including 11 patients with HER2-positive tumors treated in a neo-adjuvant setting with trastuzumab was performed. Trastuzumab was administered i.v. at a dose of 4 mg/kg followed by three weekly i.v. doses of 2 mg/kg. The primary tumor was surgically removed 7 days after the last treatment. Surgical samples, tumor biopsies, and lymphocytes from these patients were collected for biological studies. RESULT: Clinical data indicated one complete pathological remission and four partial remissions using RECIST (Response Evaluation Criteria in Solid Tumors). Trastuzumab was well tolerated and neither serious adverse events nor changes in cardiac function were observed during this short-term treatment and after surgery. The biological data showed that, independent of response, (a) all patients showed high levels of circulating trastuzumab; (b) saturating level of trastuzumab was present in all of the tumors; (c) no down-modulation of HER2 was observed in any tumors; (d) no changes in vessel diameter was observed in any tumors; (e) no changes in proliferation was observed in any tumors; and (f) a strong infiltration by lymphoid cells was observed in all cases. Patients with complete remission or partial remission were found to have a higher in situ infiltration of leukocytes and a higher capability to mediate in vitro antibody-dependent cellular cytotoxicity activity. CONCLUSIONS: The results of this pilot study argue against trastuzumab activity in patients through down-modulation of HER2 but in favor of antibody-dependent cellular cytotoxicity guiding efforts to optimize the use of trastuzumab in breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, the therapeutic activity of these mAbs correlates with the abundance of NK cells, is influenced by genetic polymorphisms affecting Fc g R functions, and can be boosted (at least preclinically) by immunotherapeutic interventions preventing NK dysfunction (e.g., IL2 or IL12 administration) (Gennari et al., 2004; Jaime-Ramirez et al., 2011; Klein et al., 2017; Kono et al., 2002; Musolino”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Gennari et al., 2004
Experimental — accuracy not yet measuredIn the citing paper
“A follow-up study found that the quantity and lytic efficiency of CD16(+) lymphocytes are the major factors affecting the level of ADCC induced by trastuzumab. This, in turn, correlates with tumor response (Gennari et al., 2004).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Gennari et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab is a high-affinity humanized monoclonal antibody that has been shown to produce response rates of 15–40% when used as single agent in patients with metastatic HER2overexpressing breast cancer (1) and to prolong survival when combined with chemotherapy in the first-line therapy of such patients (2).”
BackgroundInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“All together, these preliminary data are strongly consistent with earlier observation from in vivo preclinical models indicating that the engagement of the Fc of trastuzumab with FcR is required for the majority of trastuzumab activity in the BT474 xenograft model (5) but do not support the role of other mechanisms su…”
BackgroundResultVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Pross, H. F., Baines, M. G., Rubin, P., Shragge, P., & Patterson, M. S. (1981) · Journal of Clinical Immunology · doi:10.1007/bf00915477 · Cited by 691
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 1×
“Note that taxane treatment, which synergizes with trastuzumab, induces immunosuppression of adaptive immunity, but selectively increases NK activity (13).”
BackgroundBurstein, H. J., Harris, L. N., Gelman, R., Lester, S. C., Nunes, R. A., Kaelin, C. M., Parker, L. M., Ellisen, L. W., Kuter, I., Gadd, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.124 · Cited by 280
Measuring the clinical response. What does it mean?
Therasse, P. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00182-x · Cited by 132
Green, S. K., Karlsson, M. C. I., Ravetch, J. V., & Kerbel, R. S. (2002) · PubMed · Cited by 84
Cited by
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
“This, in turn, correlates with tumor response (Gennari et al., 2004).”
Background
Metadata
- Authors
- Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, B., Ballardini, B., Prada, G. D., Zambelli, A., & Costa, A.
- Affiliations
- European Institute of Oncology (IT)
- 2Department of Experimental Oncology, Molecular Targeting Unit, Istituto Nazionale Tumori, Milano, Italy;
- Fondazione Salvatore Maugeri (IT)
- 4Division of Medical Oncology and
- Istituti Clinici Scientifici Maugeri (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Policlinico San Matteo Fondazione (IT)
- MultiMedica (IT)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2004-09-01
- Volume
- 10
- Issue
- 17
- Pages
- 5650-5655
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2107426197
- Cited by
- 516
- References
- 13
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 16 · 2023: 20 · 2022: 18 · 2021: 17 · 2020: 16 · 2019: 22 · 2018: 20 · 2017: 16 · 2016: 22 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 31
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- American-Italian Cancer Foundation
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- trastuzumab, HER2-positive breast cancer, mechanism of action, neoadjuvant therapy, antibody-dependent cellular cytotoxicity, lymphocyte infiltration, tumor vascularization, tumor cell proliferation, pathological complete response
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Lymphocytes, Pilot Projects, Preoperative Care, Remission Induction, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0225
- The paper
- Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, B., Ballardini, B., Prada, G. D., Zambelli, A., & Costa, A. (2004). Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.